interacts_with DB01120?
Sulfonylureas inhibit cytokine-induced eosinophil survival and activation . Eosinophils play a key role in the pathogenesis of asthma and other allergic inflammatory diseases . We have previously shown that treatment of eosinophils with lidocaine preferentially inhibits P05113 -induced survival . This inhibition can not be overcome by increasing concentrations of P05113 and is not due to the blocking of Na+ channels by lidocaine . Here we report that one class of K+ channel blockers , the sulfonylureas , inhibits eosinophil survival in a manner similar to lidocaine . The sulfonylurea glyburide inhibits eosinophil survival even at high concentrations of P05113 . In contrast , increasing concentrations of P08700 or granulocyte-macrophage P04141 overcome glyburide inhibition . Glyburide also blocks cytokine-induced eosinophil superoxide production . Similar results were seen with the sulfonylureas tolbutamide and glipizide . Interestingly , the effects of glyburide are not antagonized by the DB00171 -sensitive K+ channel openers cromakalim , pinacidil , or diazoxide . Although Scatchard analysis of [3H]glyburide binding to eosinophil membranes indicated that the high affinity sulfonylurea receptor ( Q09428 ) is not present on eosinophils , human eosinophils do express mRNA homologous to the sulfonylurea receptor family , in keeping with the presence of a sulfonylurea receptor . Finally , coculture of eosinophils with combinations of glyburide , lidocaine , and dexamethasone resulted in synergistic inhibition of cytokine-mediated eosinophil survival and superoxide production . These results have intriguing clinical implications for the treatment of eosinophil-associated diseases . Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries . BACKGROUND : Atherosclerosis affects aorta , coronary , carotid , and iliac arteries most frequently than any other body vessel . There may be common molecular pathways sustaining this process . Plaque presence and diffusion is revealed by circulating factors that can mediate systemic reaction leading to plaque rupture and thrombosis . RESULTS : We used DNA microarrays and meta-analysis to study how the presence of calcified plaque modifies human coronary and carotid gene expression . We identified a series of potential human atherogenic genes that are integrated in functional networks involved in atherosclerosis . Caveolae and JAK/ P35610 pathways , and P06702 / P05109 interacting proteins are certainly involved in the development of vascular disease . We found that the system of caveolae is directly connected with genes that respond to hormone receptors , and indirectly with the apoptosis pathway . Cytokines , chemokines and growth factors released in the blood flux were investigated in parallel . High levels of RANTES , IL-1ra , MIP-1 alpha , MIP-1 beta , P60568 , P05112 , P05113 , P05231 , P13232 , Q16552 , DB00102 , P15692 and P01579 were found in plasma of atherosclerotic patients and might also be integrated in the molecular networks underlying atherosclerotic modifications of these vessels . CONCLUSION : The pattern of cytokine and P06702 / P05109 up-regulation characterizes atherosclerosis as a proinflammatory disorder . Activation of the JAK/ P35610 pathway is confirmed by the up-regulation of P05231 , P42224 , Q00978 and Q13651 genes in coronary and carotid plaques . The functional network constructed in our research is an evidence of the central role of P35610 protein and the caveolae system to contribute to preserve the plaque . Moreover , Cav-1 is involved in SMC differentiation and dyslipidemia confirming the importance of lipid homeostasis in the atherosclerotic phenotype . Regulation of Q9BYW2 {alpha} activity in adipose tissue by obesity-associated factors : adipogenesis , insulin , and hypoxia . The transcription factor HIF-1α activity is increased in adipose tissue to contribute to chronic inflammation in obesity . However , its upstream and downstream events remain to be characterized in adipose tissue in obesity . We addressed this issue by investigating adipocyte HIF-1α activity in response to obesity-associated factors , such as adipogenesis , insulin , and hypoxia . In adipose tissue , both HIF-1α mRNA and protein were increased by obesity . The underlying mechanism was investigated in 3T3- Q9NUQ9 adipocytes . HIF-1α mRNA and protein were augmented by adipocyte differentiation . In differentiated adipocytes , insulin further enhanced HIF-1α in both levels . Hypoxia enhanced only HIF-1α protein , not mRNA . PI3K and P42345 activities are required for the HIF-1α expression . Function of HIF-1α protein was investigated in the regulation of P15692 gene transcription . ChIP assay shows that HIF-1α binds to the proximal hypoxia response element in the P15692 gene promoter , and its function is inhibited by a corepressor composed of O15379 and Q9Y618 . These observations suggest that of the three obesity-associated factors , all of them are able to augment HIF-1α protein levels , but only two ( adipogenesis and insulin ) are able to enhance HIF-1α mRNA activity . Adipose tissue HIF-1α activity is influenced by multiple signals , including adipogenesis , insulin , and hypoxia in obesity . The transcriptional activity of HIF-1α is inhibited by O15379 - Q9Y618 corepressor in the P15692 gene promoter . Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products : inhibitory effect of gliclazide . AIM : We have previously demonstrated that advanced glycation end products ( AGEs ) stimulate bovine retinal endothelial cell ( BREC ) proliferation through induction of vascular endothelial growth factor ( P15692 ) production by these cells . We have also shown that gliclazide , a sulfonylurea which decreases oxidative stress , inhibits this effect . The aim of the present study was to characterize the signalling pathways involved in P51606 -induced BREC proliferation and P15692 production and mediating the inhibitory effect of gliclazide on these biological events . METHODS : BRECs were treated or not treated with AGEs in the presence or absence of gliclazide , antioxidants , protein kinase C ( PKC ) , mitogen-activated protein kinase ( MAPK ) or nuclear factor-kappaB ( NF-kappaB ) inhibitors . BREC proliferation was assessed by measuring [ 3H ] -thymidine incorporation into DNA . Activation of PKC , MAPK and NF-kappaB signal transduction pathways and determination of P15692 expression were assessed by Western blot analysis using specific antibodies . MAPK activity was also determined by an in vitro kinase assay . RESULTS : Treatment of BRECs with AGEs significantly increased cell proliferation and P15692 expression . AGEs induced P05771 translocation , extracellular signal-regulated protein kinase 1/2 and NF-kappaB activation in these cells . Pharmacological inhibition of these signalling pathways abolished P51606 effects on cell proliferation and P15692 expression . Exposure of BRECs to gliclazide or antioxidants such as vitamin E or N-acetyl-l-cysteine resulted in a significant decrease in P51606 -induced activation of PKC- , MAPK- and NF-kappaB-signalling pathways . CONCLUSIONS : Our results demonstrate the involvement of PKC , MAPK and NF-kappaB in P51606 -induced BREC proliferation and P15692 expression . DB01120 inhibits BREC proliferation by interfering with these intracellular signal transduction pathways . APELIN promotes hematopoiesis from human embryonic stem cells . Transcriptional profiling of differentiating human embryonic stem cells ( hESCs ) revealed that Q9H2W2 -positive mesodermal precursors were enriched for transcripts encoding the G-protein-coupled APELIN receptor ( P35414 ) . P35414 -positive cells , identified by binding of the fluoresceinated peptide ligand , APELIN ( Q9ULZ1 ) , or an anti- P35414 mAb , were found in both posterior mesoderm and anterior mesendoderm populations and were enriched in hemangioblast colony-forming cells ( Bl- Q15814 ) . The addition of Q9ULZ1 peptide to the media enhanced the growth of embryoid bodies ( EBs ) , increased the expression of hematoendothelial genes in differentiating hESCs , and increased the frequency of Bl-CFCs by up to 10-fold . Furthermore , Q9ULZ1 peptide also synergized with P15692 to promote the growth of hESC-derived endothelial cells . These studies identified Q9ULZ1 as a novel growth factor for hESC-derived hematopoietic and endothelial cells . P01308 action on H292 bronchial carcinoma cells as compared to normal bronchial epithelial cells . DB00030 may contribute to bronchial carcinoma due to P08069 activation by high local concentrations . Therefore , effects of insulin and P05019 on human bronchial carcinoma cells ( H292 ) and normal bronchial epithelium cells ( P02100 ) were studied . TGF-β was included since it also influences carcinoma progression . H292 and P02100 cells expressed both the insulin receptor and the P08069 ; in H292 cells an additional , shorter , splicing variant ( IR-A ) of the insulin receptor was present . P06213 expression was around four to five times higher in H292 than in P02100 cells at mRNA and protein levels . P01308 and TGF-β exerted contrary actions on proliferation and gene expression in H292 cells . Genes regulated by insulin , P05019 , and TGF-β were linked to inflammation , cell adhesion , muscle contraction and differentiation . P01308 and P05019 also suppressed DNA repair genes . EC(50) for insulin-induced proliferation was around 5 nM in H292 and around 30 nM P02100 cells . The EC(50) values for gene expression ranged from 9 to 90 nM in both cell types , dependent on the gene studied . In H292 cells , the proliferative response was much stronger if TGF-β was present . In P02100 cells this interaction of insulin and TGF-β was not observed , and changes in gene expression were mostly lower by at least 10-fold as compared to H292 . All in all , the insulin effects in H292 were generally much stronger than in P02100 cells and - with regard to proliferation - occurred at lower concentrations . Thus , insulin will hardly induce cancer from normal bronchial cells but may favour progression of pre-existing tumours . Inhibition of human brain and RBC acetylcholinesterase ( P22303 ) by heptylphysostigmine ( HPTL ) . Heptylphysostigmine ( HPTL ) , a derivative of the P22303 inhibitor physostigmine ( PHY ) , is under investigation as a therapeutic agent in Alzheimer 's disease . HPTL is active against human RBC P22303 both in vitro and in vivo . Activity of HPTL against human brain has not been documented . We have developed an in vitro assay system using particulate membrane fractions which permits comparison of inhibition and recovery kinetics of human RBC ( primarily globular dimer ) and brain ( primarily globular tetramer ) membrane-bound forms . Under these conditions the HPTLIC50 is similar for the two forms . RBC P22303 inhibition spontaneously reverses in 24 h , as occurs in vivo . In striking contrast , activity of inhibited brain enzyme does not recover on overnight incubation . DDVP-induced inhibition , but not HPTL inhibition , can be reversed by the oxime DB00733 . Some recovery of HPTL inhibition , but not to the level seen with RBC P22303 , occurs on addition of heat-stable fractions from serum or P04141 . Brain enzyme recovers rapidly from PHY in this system . Responses of brain and RBC P22303 to HPTL indicate that these forms are functionally as well as structurally distinct . Since brain inhibition apparently does not spontaneously reverse like RBC inhibition , peripheral measurements of patient responses should be assessed with caution during treatment with HPTL . DB01892 is a dual inhibitor of cyclooxygenase-1 and P09917 . The acylphloroglucinol derivative hyperforin is the major lipophilic constituent in the herb Hypericum perforatum ( St. John 's wort ) . The aim of the present study was to investigate if hyperforin as well as extracts of H. perforatum can suppresses the activities of P09917 ( P09917 ) and cyclooxygenases ( P36551 ) , key enzymes in the formation of proinflammatory eicosanoids from arachidonic acid ( AA ) . In freshly isolated human polymorphonuclear leukocytes stimulated with Ca(2+) ionophore A23187 , hyperforin inhibited P09917 product formation with IC(50) values of about 1-2 microM , in the absence or presence of exogenous AA ( 20 microM ) , respectively , being almost equipotent to the well-documented P09917 inhibitor zileuton ( IC(50) = 0.5-1 microM ) . Experiments with purified human P09917 demonstrate that hyperforin is a direct P09917 inhibitor ( IC(50) approximately 90 nM ) , acting in an uncompetitive fashion . In thrombin- or ionophore-stimulated human platelets , hyperforin suppressed P23219 product ( 12(S)-hydroxyheptadecatrienoic acid ) formation with an IC(50) of 0.3 and 3 microM , respectively , being about 3- to 18-fold more potent than aspirin . At similar concentrations , hyperforin suppressed P23219 activity in platelets in presence of exogenous AA ( 20 microM ) as well as in cell-free systems . DB01892 could not interfere with P35354 product formation and did not significantly inhibit 12- or 15-LO in platelets or leukocytes , respectively . We conclude that hyperforin acts as a dual inhibitor of P09917 and P23219 in intact cells as well as on the catalytic activity of the crude enzymes , suggesting therapeutic potential in inflammatory and allergic diseases connected to eicosanoids . Permanent neonatal diabetes mellitus in China . BACKGROUND : Permanent neonatal diabetes mellitus ( PNDM ) is a rare disease , which is defined as the onset of diabetes before the age of 6 months with persistence through life . Infants with Q14654 or Q09428 genetic mutations may respond to oral sulfonylurea therapy . Currently , there are limited studies about the genetic analysis and long-term follow-up of PNDM . CASE PRESENTATION : We report four cases of PNDM . None of the infants or their parents had P01308 , Q14654 , or Q09428 genetic mutations . One infant underwent continuous subcutaneous insulin infusion ( CSII ) and the other infants underwent multiple injections of insulin ( MII ) . In these infants , PNDM persisted from 35 months to 60 months of follow-up . Three infants maintained fairly stable blood sugar levels , and one infant had poor sugar control . CONCLUSIONS : We suggest that all of the infants with PNDM should undergo genetic evaluation . For infants without Q14654 and Q09428 genetic mutations , oral sulfonylurea should not be considered as treatment . CSII is a useful method for overcoming the difficulties of diabetes , and it may also improve the quality of life of both infants and their parents . DB04901 ( IDEC ) . IDEC is developing a PRIMATIZED-anti- P33681 antibody ( DB04901 ) for the treatment of autoimmune and inflammatory diseases , such as psoriasis and rheumatoid arthritis . It is currently undergoing phase II trials in patients with psoriasis [ 395813 ] . A randomized , blind , placebo-controlled , multiple-dose phase II study was initiated in January 2001 to evaluate the potential clinical activity and safety of DB04901 in patients with moderate-to-severe psoriasis [ 395813 ] . The antibody targets the P33681 antigen on the surface of antigen-presenting cells that normally interact with T-cells to initiate an immune response . Antibodies directed at P33681 may be useful in preventing unwanted immune responses in autoimmune diseases such as systemic lupus erythematosus , idiopathic thrombocytopenic purpura as well as transplant rejection [ 178382 ] , [ 178929 ] . PRIMATIZED antibodies , genetically engineered from cynomolgus macaque monkey and human components , are structurally indistinguishable from human antibodies . They may , therefore , be less likely to cause adverse reactions in humans , making them potentially suited for long-term , chronic treatment [ 244805 ] . IDEC has signed an antibody humanization patent licensing agreement with Protein Design Labs [ 240591 ] . IDEC is also collaborating with Mitsubishi-Tokyo ( formerly Mitsubishi Kasei ) on the development of this antibody [ 178382 ] . Management of ocular inflammation and pain following cataract surgery : focus on bromfenac ophthalmic solution . Recently , several new ophthalmic NSAID products have been introduced for commercial use in the United States . The purpose of this review is to briefly overview the ophthalmic NSAIDs currently in use and to discuss the management of postoperative ocular inflammation and pain following cataract surgery with a particular focus on bromfenac ophthalmic solution 0.09 % . DB00963 ophthalmic solution 0.09 % is indicated for the reduction of ocular pain and inflammation following cataract surgery . Studies have shown that bromfenac ophthalmic solution 0.09 % has equivalent efficacy to the other topical NSAIDs in reducing postsurgical inflammation and controlling pain . The unique chemical structure of bromfenac makes it both a potent inhibitor of the P35354 enzyme and a highly lipophilic molecule that rapidly penetrates to produce early and sustained drug levels in all ocular tissues . Clinically , these pharmacokinetic features are manifested in a rapid reduction of postsurgical inflammation and pain with bid dosing . DB00963 ophthalmic solution 0.09 % is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids . Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics . Restricting the cytotoxicity of anticancer agents by targeting receptors exclusively expressed on tumor cells is critical when treating infiltrative brain tumors such as glioblastoma multiforme ( GBM ) . GBMs express an P35225 receptor ( IL13Rα2 ) that differs from the physiological P24394 /IL13R receptor . We developed a regulatable adenoviral vector ( Ad.mhIL-4.TRE.mhIL-13-PE ) encoding a mutated human P35225 fused to Pseudomonas exotoxin ( mhIL-13-PE ) that specifically binds to IL13Rα2 to provide sustained expression , effective anti-GBM cytotoxicity , and minimal neurotoxicity . The therapeutic Ad also encodes mutated human P05112 that binds to the physiological P24394 /IL13R without interacting with IL13Rα2 , thus inhibiting potential binding of mhIL-13-PE to normal brain cells . Using intracranial GBM xenografts and syngeneic mouse models , we tested the Ad.mhIL-4.TRE.mhIL-13-PE and two protein formulations , hIL-13-PE used in clinical trials ( DB05305 ) and a second-generation mhIL-13-PE . DB05305 doubled median survival without eliciting long-term survival and caused severe neurotoxicity ; mhIL-13-PE led to ∼40 % long-term survival , eliciting severe neurological toxicity at the high dose tested . In contrast , Ad-mediated delivery of mhIL-13-PE led to tumor regression and long-term survival in over 70 % of the animals , without causing apparent neurotoxicity . Although DB05305 was originally developed to target GBM , when tested in a phase III trial it failed to achieve clinical endpoints and revealed neurotoxicity . Limitations of DB05305 include its short half-life , which demanded frequent or continued administration , and binding to P24394 /IL13R , present in normal brain cells . These shortcomings were overcome by our therapeutic Ad , thus representing a significant advance in the development of targeted therapeutics for GBM . Regulatory regions of growth-related genes can activate an exogenous gene of the alpha-fetoprotein promoter to a comparable degree in human hepatocellular carcinoma cells . We examined the transcriptional activation by the regulatory regions of the midkine ( MK ) , survivin ( Q09428 ) , cyclooxygenase-2 ( P35354 ) , telomerase reverse transcriptase ( O14746 ) and alpha-fetoprotein ( AFP ) genes in human hepatocellular carcinoma cells . Luciferase assays showed that the Q09428 regulatory region exhibited the greatest activity and that the MK regulatory region activated the reporter gene better than the enhancer-linked AFP promoter even in high-AFP-producing cells . The P35354 and O14746 regulatory regions also activated the reporter gene better than the AFP enhancer/promoter in intermediate-AFP-producing cells . Combination of the regulatory regions arranged in tandem modulated their transcriptional activities , depending on the arrangement of the promoters and cells examined . These data suggested that the regulatory regions of the growth-related genes could be useful to activate a therapeutic gene in hepatocellular carcinoma cells irrespective of the amounts of AFP production but combinatory use of the promoter regions could not always contribute to enhanced activity . The v-ErbA oncoprotein quenches the activity of an erythroid-specific enhancer . v-ErbA is a mutated variant of thyroid hormone receptor ( TRalpha/ P10827 ) borne by the Avian Erythroblastosis virus causing erythroleukemia . TRalpha is known to activate transcription of specific genes in the presence of its cognate ligand , DB00279 hormone , while in its absence it represses it . v-ErbA is unable to bind ligand , and hence is thought to contribute to leukemogenesis by actively repressing erythroid-specific genes such as the carbonic anhydrase II gene ( CA II ) . In the prevailing model , v-ErbA occludes liganded TR from binding to its cognate elements and constitutively interacts with the corepressors NCoR/ Q9Y618 . We previously identified a v-ErbA responsive element ( VRE ) within a P24855 hypersensitive region ( Q5VYS8 ) located in the second intron of the CA II gene . We now show that Q5VYS8 fulfils all the requirements for a genuine enhancer that functions independent of its orientation and position with a profound erythroid-specific activity in normal erythroid progenitors ( T2ECs ) and in leukemic erythroid cell lines . We find that the Q5VYS8 enhancer activity is governed by two adjacent GATA-factor binding sites . v-ErbA as well as unliganded TR prevent Q5VYS8 activity by nullifying the positive function of factors bound to GATA-sites . However , v-ErbA , in contrast to TR , does not convey active repression to silence the transcriptional activity intrinsic to a heterologous tk promoter . We propose that depending on the sequence and context of the binding site , v-ErbA contributes to leukemogenesis by occluding liganded TR as well as unliganded TR thereby preventing activation or repression , respectively . Protective effect of treatment with low-dose gliclazide in a model of middle cerebral artery occlusion and reperfusion in rats . The aim of this study was to explore the expression of sulfonylurea receptor 1 ( Q09428 ) , the regulatory subunit of the NCCa- DB00171 channel , and to investigate the protective effects of gliclazide following middle cerebral artery occlusion ( MCAO ) /reperfusion in male Wistar rats . Adult rats underwent 2h of the left MCAO using the intraluminal thread technique before reperfusion . The core areas of the infarct at different reperfusion time points were examined for the mRNA level and protein expression of Q09428 using reverse transcription-polymerase chain reaction ( RT-PCR ) and western blotting respectively . DB01120 was administered intravenously into the right jugular vein for 12h simultaneously with the reperfusion . The number of apoptotic cells was determined using the TUNEL assay . The neurological functional deficits were evaluated using Bederson׳s test , and the cerebral infarction volume was visualized with TTC staining . We found up-regulation of Q09428 mRNA and protein levels in ischemic infarct tissues after reperfusion following MCAO , and Q09428 mRNA and protein were maximally upregulated 8-12h after a 2-hour ischemia . The treatment with low-dose of gliclazide reduced the total number of TUNEL-positive cells , the neurological functional deficits and the brain infarct volume . These results suggest that the Q09428 -regulated NCCa- DB00171 channel may be associated with MCAO/reperfusion injury and the infarct-reducing effects of intravenous treatment with gliclazide may be due , in part , to the blocked upregulation of Q09428 expression , the decreased infarct size and the reduced apoptosis in the ischemia-reperfusion brain . Human umbilical cord Wharton 's jelly stem cells : immune property genes assay and effect of transplantation on the immune cells of heart failure patients . Stem cells derived from umbilical cord Wharton 's jelly ( WJSCs ) are not immunogenic and have immunosuppressive effects . To evaluate the related mechanisms and the effect of transplantation on body immune cells , we examined immune property genes expression in WJSCs and levels of T-lymphocytes subgroups and immunoglobulins ( Ig ) in heart failure ( HF ) patients with and without WJSCs transplantation . WJSCs express immune tolerance genes P13747 , P17693 and P30511 and immunomodulation genes P15692 , TGFβ1 , P14210 , P09601 , IL1β , P05231 , P15018 , LGALS-1/3/8 , P23219 /2 and PTGE , while they do not express immune response-related genes HLA-DR , HLA-DQ , HLA-DP , P33681 , P42081 , P25942 and P29965 . No obvious changes of T-lymphocytes subgroups and plasma IgG/IgM were observed in HF patients with WJSCs transplantation . Our results suggest that the immune properties of WJSCs are due to the expression of immune avoidance and immunomodulation genes in the absence of immune response-related genes . WJSCs are secure in immunological aspects when used as seed cells for cardiac repair . Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity . Vascular endothelial growth factor ( P15692 ) and its endothelial cell receptors ( VEGFR ) have been shown to be involved in the pathogenesis of the contact hypersensitivity ( Q99698 ) reaction . Previous studies have demonstrated that anti- P35968 antibody significantly suppresses the elicitation phase of Q99698 but does not affect the induction phase . PTK787/ZK 222584 ( 1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine succinate ; DB04879 ) is a potent inhibitor of VEGFR tyrosine kinases . To test the effect of DB04879 on the induction and elicitation phases of Q99698 separately , we used an established method of Q99698 assay-sensitization and challenge in BALB/c mice . Either 50 mg/kg/day DB04879 or vehicle serving as a control was administered orally in the induction or elicitation phases separately . In the afferent phase , flow cytometry of skin-draining lymph node cells revealed that the migration of Langerhans cells was suppressed in the mice treated with DB04879 at sensitization . The degrees of ear swelling at 24 and 48 h were significantly diminished in mice treated with DB04879 at sensitization ( P < 0.05 ) . In the efferent phase , the degrees of ear swelling at 24 h ( P < 0.01 ) and 48 h ( P < 0.05 ) , ear blood flow at 24 and 48 h ( P < 0.01 ) , and production of P15692 in the epidermis at 24 h ( P < 0.05 ) were significantly suppressed in mice treated with DB04879 at elicitation . These findings and previous demonstrations suggest that both P15692 R-1 and P15692 R-2 are needed during the induction phase , and that P35968 has a pivotal role in the elicitation phase of the Q99698 reaction . P08473 -blocking agent thiorphan affects cell growth and differentiation in long term culture of mouse bone marrow . P08473 -blocking agent thiorphan was added to long-term cultures of mouse bone marrow cells at the time of culture initiation ( time 0 ) or 2 weeks thereafter , when the stromal layer appears . Cellularity , cell morphology ( in cytospin smears ) and the yield of granulocyte-macrophage progenitor cells ( GM- Q15814 assay in agar ) were recorded . Low concentrations of thiorphan accelerated recovery of the cultures after an initial drop of the cell count . Expansion and maturation of the granulocytic lineage was promoted , with parallel decline of the GM- Q15814 yield . DB08626 probably interfered with the activity of enkephalinase ( endopeptidase 24.11 ) in the cultures . That enzyme is the CD10 surface marker ( P08473 ) of lymphoid , myeloid and stromal elements .